John joined NEA in 1989 and became a General Partner of NEA in 1993 and became a Special Partner in October 2000. He focuses on a wide range of high-technology companies with an emphasis on healthcare services, information systems and medical devices. Current board memberships include Cardionomic, CVRx, Davita Healthcare Partners, Denali II Medical, Exploramed III, Ivantis, Moximed, NeoTract, Prospex Medical III, Rotation Medical, Van Gogh Imaging and VytronUS. His prior board memberships include among others, Acclarent (acquired by Johnson & Johnson), Apnex Medical, Bridge Medical (acquired by Amerisource Bergen), Celeris Corporation (assets sold), EndoMatrix (acquired by C.R. Bard), Evalve Inc. (acquired by Abbott), Integrated Telecom (acquired by PMC Sierra), IRIDEX Corporation, Minerva Medical, Optical Sensors, Primax Recoveries (acquired by ACS Corp.), Proxima Therapeutics (acquired by CYTEC Corporation) , Surgical Health (acquired by HealthSouth), TargetRx, TELOGY Networks (acquired by Texas Instruments), TransVascular (acquired by Medtronic) Vibrynt, and Vivra (acquired by Gambro ab). Prior to joining NEA in 1989, John was a Managing Director of Alex. Brown & Sons with primary responsibility for developing the firm's healthcare research, investment banking and capital markets businesses. He has also served since 1989 as the Managing General Partner of Catalyst Ventures. John is a Board member of the Baltimore School for the Arts. He received his BA from the University of Michigan.